Trademark: 77617054
Word
MORROWGENIX
Status
Dead
Status Code
606
Status Date
Monday, September 17, 2012
Serial Number
77617054
Mark Type
4000
Filing Date
Tuesday, November 18, 2008
Published for Opposition
Tuesday, November 24, 2009
Abandoned Date
Monday, September 17, 2012

Trademark Owner History
CosGenix, LLC - Owner At Publication

Classifications
1 Biological tissue, namely, blood, fat derived stem cells, fat derived collagen, collagen, cells, stem cells, umbilical cords and placentas for scientific and clinical research use
3 Cosmetic preparations for skin renewal; non-medicated skin care preparations; skin moisturizer; non-medicated skin care preparation for use in treating sun burn and chapping; sunscreen; skin preparations for UV protection in the nature of sun block; non-medicated skin care preparations for use in cosmetic peels; skin gel; cosmetics; medicated biologic compounds in the form skin soap
5 Medicines for the treatment of aging, cosmetic appearance, wrinkles, dermal defects, wound healing, revascularization, skin laxity, skin redundancy, skin deformity, scar tissue, facial aging, facial rejuvenation, facial reconstruction, body rejuvenation, body reconstruction, body contouring, body augmentation, breast augmentation, buttock augmentation, mons augmentation, nasal augmentation, urinary incontinence, and erectile dysfunction; biological tissue, namely, blood, fat derived stem cells, fat derived collagen, collagen, cells, stem cells, umbilical cords and placentas for medical use; pharmaceuticals, namely, pharmaceutical skin lotions, antiinfective preparations, medicated anti-aging skin creams and lotions; medicated biologic compounds in the form of body lotion, skin lotion, skin creams, skin adjuvants, skin astringents, skin stimulants, skin regenerants, skin powder, skin oil, skin gel, skin moisturizer, skin colloid, and skin hydroge; medicated skin serums; biologic product, namely, human allograft, autograft, and xenograft tissue; biologic derivatives, namely, autologous cells, allogeneic cells, and cells for medical or clinical use; medicated serums for treatment of wounds, scars, burns, skin defects, cosmetic appearance, breast augmentation, limb regeneration, limb amputation, aging, wrinkles, dermal defects, wound healing, tissue revascularization, skin laxity, skin redundancy, skin deformity, scar tissue, facial aging, facial rejuvenation, facial reconstruction, body rejuvenation, body reconstruction, body contouring, body augmentation, buttock augmentation, mons augmentation, nasal augmentation, urinary incontinence, and erectile dysfunction; biological derivatives in the nature of cell membranes, cell proteins, extracellular matrix, hormones, neurotransmitters, hormone precursors, neurotransmitter precursors, signal transduction molecules, aromatic hydrocarbons, proteins, amino acids, carbohydrates, nucleic acids, DNA, RNA, phospholipids, lipids, electrolytes, and antibodies for medical use; conditioned media, namely, tissue culture media, tissue culture serums, and tissue culture additives for medical use; lyophilized agents, namely, freeze dried cells, cell extract, cell organelles, protein, lipids, and carbohydrates for medical use; medicated serums for use in tissue culture, scar tissue repair, body augmentation, fat removal, fat augmentation, wound healing, wound repair, tissue regeneration, and anti-aging; dermal filler, injectable dermal fillers, adjuvants for medical purposes; human allograft, autograft, and xenograft tissue; herbals, namely, herbal supplements
10 medical devices, namely, a fat processing device for isolating adipose derived stem cells, precursor/progenitor cells, and/or fibroblasts from fat, and a cell isolation system primarily featuring a cell isolation device to produce fatty tissue enriched with adipose derived stem cells and/or isolate pure populations and subsets of adipose derived stem cells, fibroblasts or dermal, neuron, vascular, cartilage, muscle or bone progenitor/precursor cells; cell isolation devices for treatment of aging, cosmetic appearance, wrinkles, dermal defects, wound healing, revascularization, skin laxity, skin redundancy, scar tissue, facial rejuvenation, facial reconstruction, body rejuvenation, body reconstruction, urinary incontinence, erectile dysfunction, wounds, scars, burns, skin defects, breast augmentation, limb regeneration, limb amputation, tissue revascularization, skin deformity, facial aging, body contouring, body augmentation, buttock augmentation, mons augmentation, and nasal augmentation
44 Cosmetic and plastic surgery
MORROW COSGENIX; MORROW COSMETIC GENIX

Trademark Events
Sep 17, 2012
Abandonment Notice Mailed - No Use Statement Filed
Sep 17, 2012
Abandonment - No Use Statement Filed
Feb 17, 2012
Notice Of Approval Of Extension Request Mailed
Feb 16, 2012
Extension 4 Granted
Feb 9, 2012
Extension 4 Filed
Feb 9, 2012
Teas Extension Received
Aug 2, 2011
Notice Of Approval Of Extension Request Mailed
Aug 1, 2011
Extension 3 Granted
Jul 26, 2011
Extension 3 Filed
Jul 26, 2011
Teas Extension Received
Jan 5, 2011
Notice Of Approval Of Extension Request Mailed
Jan 4, 2011
Extension 2 Granted
Dec 7, 2010
Extension 2 Filed
Jan 4, 2011
Case Assigned To Intent To Use Paralegal
Dec 7, 2010
Teas Extension Received
Jul 28, 2010
Notice Of Approval Of Extension Request Mailed
Jul 26, 2010
Extension 1 Granted
Jul 26, 2010
Extension 1 Filed
Jul 26, 2010
Teas Extension Received
Feb 16, 2010
Noa Mailed - Sou Required From Applicant
Nov 24, 2009
Published For Opposition
Nov 4, 2009
Notice Of Publication
Oct 20, 2009
Law Office Publication Review Completed
Oct 19, 2009
Examiners Amendment Mailed
Oct 19, 2009
Approved For Pub - Principal Register
Oct 19, 2009
Examiner's Amendment Entered
Oct 19, 2009
Examiners Amendment -Written
Oct 19, 2009
Previous Allowance Count Withdrawn
Oct 2, 2009
Withdrawn From Pub - Og Review Query
Sep 24, 2009
Law Office Publication Review Completed
Sep 24, 2009
Approved For Pub - Principal Register
Sep 23, 2009
Examiners Amendment Mailed
Sep 22, 2009
Examiner's Amendment Entered
Sep 22, 2009
Examiners Amendment -Written
Sep 22, 2009
Examiners Amendment Mailed
Sep 22, 2009
Examiner's Amendment Entered
Sep 22, 2009
Examiners Amendment -Written
Sep 21, 2009
Examiners Amendment Mailed
Sep 18, 2009
Examiner's Amendment Entered
Sep 18, 2009
Examiners Amendment -Written
Sep 9, 2009
Teas/Email Correspondence Entered
Sep 9, 2009
Correspondence Received In Law Office
Sep 8, 2009
Teas Request For Reconsideration Received
Jul 27, 2009
Final Refusal Mailed
Jul 27, 2009
Final Refusal Written
Jul 6, 2009
Teas/Email Correspondence Entered
Jul 6, 2009
Correspondence Received In Law Office
Jul 2, 2009
Teas Response To Office Action Received
May 1, 2009
Teas Change Of Correspondence Received
Feb 20, 2009
Non-Final Action Mailed
Feb 19, 2009
Non-Final Action Written
Feb 17, 2009
Assigned To Examiner
Jan 2, 2009
Applicant Amendment Prior To Examination - Entered
Jan 2, 2009
Assigned To Lie
Dec 15, 2008
Teas Voluntary Amendment Received
Nov 22, 2008
Notice Of Pseudo Mark Mailed
Nov 21, 2008
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24